Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Randomized Comparison of Melphalan 200 Mg/m 2 v. 280 Mg/m 2 As a Preparative Regimen for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

William I. Bensinger, MD, Pamela S Becker, MD, PhD, Ted A. Gooley, PhD, Thomas Chauncey, MD, PhD, David G. Maloney, MD, PhD, Robert Vescio, MD, Ajay K. Gopal, MD, Damian J. Green, MD, Oliver W. Press, MD, PhD, Michael Lill, M.D., Leona Holmberg, MD, PhD, Jainulabdeen J Ifthikharuddin, MD, Gordon L. Phillips, II, MD

Blood (2012) 120 (21): 2009.

https://doi.org/10.1182/blood.V120.21.2009.2009

Published: 2012

Journal Articles

Salvage Autologous Hematpoeitic Stem Cell Transplants (AHSCT2) for Myeloma: Single Center Experience.

Bishoy Faltas, MD, Jane L. Liesveld, MD, Michael Becker, Jainulabdeen J. Ifthikharuddin, MD, Gordon L. Phillips, II, MD

Blood (2010) 116 (21): 4591.

https://doi.org/10.1182/blood.V116.21.4591.4591

Published: 2010

Journal Articles

Geographic and Racial Disparities In Multiple Myeloma Outcomes In the USA

Shahrukh Hashmi, MD, MPH, Chris Mooney, MA, MPH, Gordon L. II Phillips, MD, Jane L. Liesveld, MD, Jainulabdeen J Ifthikharuddin, MD

Blood (2010) 116 (21): 2557.

https://doi.org/10.1182/blood.V116.21.2557.2557

Published: 2010

Journal Articles

Phase I Study of Cladribine, Cytarabine (Ara-C), Granulocyte Colony Stimulating Factor (G-CSF) (CLAG Regimen) and Simultaneous Escalating Doses of Imatinib Mesylate (Gleevec) in Relapsed/Refractory AML.

Camille N. Abboud, MD, Alison Walker, MD, Rami S. Komrokji, MD, Jainulabdeen J. Ifthikharuddin, MD, Connie Sparks, BS,CRA, Kelly Likly, MSN, Patti Messina, BSN, Deborah Mulford, MD, Jonathan Friedberg, MD, Michael W. Becker, MD, Faith Young, MD, Steven H. Bernstein, MD, August J. Salvado, MD, Gordon L. Phillips, MD, Jane L. Liesveld, MD

Blood (2006) 108 (11): 1958.

https://doi.org/10.1182/blood.V108.11.1958.1958

Published: 2006

Journal Articles

Phase I Study for Poor Prognosis Lymphoma: Modification of the “BEAM” (BCNU +Etoposide+ARA-C+Melphalan) Regimen with Escalating-Dose Melphalan (MEL) Using Amifostine (AF) Cytoprotection and Autologous Hematopoietic Stem Cell Transplantation (AHSCT).

Gordon L. Phillips, MD, Camille N. Abboud, MD, Steven H. Bernstein, MD, Jonathan W. Friedberg, MD, Michael W. Becker, MD, Jainulabdeen J. Ifthikharuddin, MD, Faith Young, MD, Jane L. Liesveld, MD

Blood (2006) 108 (11): 3076.

https://doi.org/10.1182/blood.V108.11.3076.3076

Published: 2006

Journal Articles

High Incidence of Thromboembolic Complications and PF4 Positivity in Patients with Ventricular Assist Devices.

Brandon J. McMahon, MD, Jainulabdeen J. Ifthikharuddin, MD, Elie Dib, MD, Leway Chen, MD, Charles W. Francis, MD, Todd H. Massey, MD

Blood (2006) 108 (11): 4083.

https://doi.org/10.1182/blood.V108.11.4083.4083

Published: 2006

Journal Articles

Improved Methodology for Detection of Mutations in the BCR-ABL Fusion Gene That Cause Resistance to the Tyrosine Kinase Inhibitor Imatinib.

Paul G. Rothberg, PhD, Roberto L. Vargas, MD, Jane L. Liesveld, MD, Jainulabdeen J. Ifthikharuddin, MD, Sharon D. Frazier, BS, Susan L. Polochock, AAS

Blood (2006) 108 (11): 2341.

https://doi.org/10.1182/blood.V108.11.2341.2341

Published: 2006

Journal Articles

Extracorporeal Photopheresis, Pentostatin, and TBI for Reduced-Intensity Preparation: Adaptation of the Tufts Experience at a Single Transplant Center.

Jane L. Liesveld, MD, Camille N. Abboud, MD, Stephen H. Bernstein, MD, Jonathan Friedberg, MD, Jainulabdeen J. Ifthikharuddin, MD, Louis S. Constine, MD, Karen L. Kaplan, MD, PhD, Lucy A. Wedow N.P., Diane D. Nichols, BS, Jamie Oliva, N.P., Maryanne Etter, N.P, Gordon L. Phillips, MD

Blood (2005) 106 (11): 5417.

https://doi.org/10.1182/blood.V106.11.5417.5417

Published: 2005

NARROW

Randomized Comparison of Melphalan 200 Mg/m 2 v. 280 Mg/m 2 As a Preparative Regimen for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

Salvage Autologous Hematpoeitic Stem Cell Transplants (AHSCT2) for Myeloma: Single Center Experience.

Geographic and Racial Disparities In Multiple Myeloma Outcomes In the USA

Phase I Study of Cladribine, Cytarabine (Ara-C), Granulocyte Colony Stimulating Factor (G-CSF) (CLAG Regimen) and Simultaneous Escalating Doses of Imatinib Mesylate (Gleevec) in Relapsed/Refractory AML.

Phase I Study for Poor Prognosis Lymphoma: Modification of the “BEAM” (BCNU +Etoposide+ARA-C+Melphalan) Regimen with Escalating-Dose Melphalan (MEL) Using Amifostine (AF) Cytoprotection and Autologous Hematopoietic Stem Cell Transplantation (AHSCT).

High Incidence of Thromboembolic Complications and PF4 Positivity in Patients with Ventricular Assist Devices.

Improved Methodology for Detection of Mutations in the BCR-ABL Fusion Gene That Cause Resistance to the Tyrosine Kinase Inhibitor Imatinib.

Extracorporeal Photopheresis, Pentostatin, and TBI for Reduced-Intensity Preparation: Adaptation of the Tufts Experience at a Single Transplant Center.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only